Singular Genomics Systems, Inc. Common Stock
OMIC
OMIC was delisted on the 20th of February, 2025.
76 hedge funds and large institutions have $149M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
10% more funds holding
Funds holding: 69 → 76 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.02% less ownership
Funds ownership: 58.29% → 55.28% (-3%)
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
42% less capital invested
Capital invested by funds: $259M → $149M (-$110M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$2.38M |
| 2 |
BlackRock
New York
|
+$2.37M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.16M |
| 4 |
State Street
Boston,
Massachusetts
|
+$893K |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$867K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.88M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.28M |
| 3 |
RCM
Revelation Capital Management
Sausalito,
California
|
-$3.14M |
| 4 |
CC
Casdin Capital
New York
|
-$2.26M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.62M |
OMIC Hedge Fund Activity: Q2 2022 in Review
76 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q2 2022, worth a combined $149M — down 42% from $259M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new OMIC positions and 6 closed out — a net gain of 9 holders — while 24 added to existing stakes and 28 trimmed.
The largest buyer was Tikvah Management, adding an estimated $2.38M. The largest seller was OrbiMed, cutting an estimated $6.88M.
- 76 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q2 2022, up from 69 in Q1 2022.
- Funds reported $149M of Singular Genomics Systems, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
- 15 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of +9 holders.
- The largest Singular Genomics Systems, Inc. Common Stock buyer in Q2 2022 was Tikvah Management, an estimated $2.38M added.
- The largest Singular Genomics Systems, Inc. Common Stock seller in Q2 2022 was OrbiMed, an estimated $6.88M sold.
Based on aggregated 13F filings for Q2 2022.